In this premiere episode of Oncopeptalks in a brand-new podcast format, we sit down with Sofia Heigis, CEO of Oncopeptides, to discuss the company’s core mission, and what it actually takes to market an advanced cancer treatment in Europe.
We’re going back to basics:
- What is the company’s flagship drug, and which patients is it intended for?
- Why has Oncopeptides launched specifically in Germany, Austria, Spain, and Italy, and not the rest of Europe?
- How long does it really take before a doctor feels ready to prescribe a new treatment to their most critically ill patients?
This episode is for anyone who wants an inside look at Oncopeptides, whether you are a new listener or have followed the company for years. The content is in Swedish only.